David M. O’Malley, MD, professor in the Department of Obstetrics and Gynecology at Ohio State University College of Medicine and director of the Division of Gynecologic Oncology at the Ohio State University Comprehensive Cancer Center, discusses data from final review of the FORWARD II phase 1b trial of mirvetuximab soravtansine plus bevacizumab (Avastin) in the treatment of patients with platinum agnostic ovarian cancer.

In the overall study population of 60 patients, the overall response rate (ORR) was 50%. Looking at the high-expressing folate receptor group, which made up half of the patient population compared to the low-expressing folate receptor, the ORR is even more pronounced by 64%, in the folate receptor alpha cohort. high. When platinum sensitivity versus platinum resistance was assessed in the high-expression alpha receptor group, the ORR was 69% vs. 59%, respectively.

O’Malley says what’s even more exciting about the data is that duration of response (DOR) persisted beyond 12 months in patients with elevated alpha folate receptor expression who were susceptible. platinum and approached 10 months in those who were platinum resistant. . In the patient population with median alpha folate receptor expression, the DOR was 8 months.

Additionally, 32 of 33 patients who exhibited elevated alpha folate receptor expression exhibited tumor shrinkage, which O’Malley said represents the most impressive waterfall pattern he has seen over time.